Prof Golay has an extensive background in quantitative MRI methods, with a particularly strong reputation in arterial spin labelling (ASL), chemical exchange saturation transfer (CEST), and relaxometry. He is CEO of Gold Standard Phantoms and Honorary Professor at University College London. His track record includes extensive application of MRI methods in neurological conditions, including stroke, multiple sclerosis, and dementia, as well as oncology.

Prof Geoff Parker, Bioxydyn’s CEO, said: “We are delighted to have Xavier on board and are looking forward to working with him on our expanding portfolio of neurological and other trials. His global reputation and skills in advanced MRI are an excellent complement to Bioxydyn’s existing capabilities, as are the capabilities he brings via Gold Standard Phantoms.”

Prof Golay, said: “I have been an admirer of Bioxydyn’s activities as an imaging CRO working in quantitative MRI methods for many years. This is a wonderful opportunity to help Bioxydyn extend its capabilities, and an excellent way for Gold Standard Phantoms to support high quality clinical studies at scale.”

Bioxydyn provides high-standard, quantitative MRI imaging services to both the pharmaceutical industry and clinical/academic R&D. With over a decade of experience delivering complex, multi-centre clinical trials, Bioxydyn employs robust GxP and 21 CFR Part 11 compliant processes, supported by their cloud-based VoxelFlow data management & analysis platform. Bioxydyn empowers its clients with unique insights into disease progression and drug effects, helps pharmaceutical companies make investment decisions and assists clinicians in developing the best treatment for patients.